Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | CCR3 | P51677 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.59 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12041242 | 0.96 | KCNH2 (0.68) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041337 | 0.95 | CARM1 (0.63) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041254 | 0.94 | CARM1 (0.64) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041232 | 0.89 | KCNH2 (0.78) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041306 | 0.89 | PRMT6 (0.59) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041299 | 0.88 | KCNH2 (0.61) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041275 | 0.87 | KCNH2 (0.64) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041272 | 0.87 | KCNH2 (0.70) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041321 | 0.86 | KCNH2 (0.61) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12040811 | 0.84 | KCNH2 (0.84) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | KCNH2 969/4885CCR3 2850/4885SIGMAR1 4049/4885 |
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | MPO, DHODH, DHX35 | KCNH2 1135/4885CCR3 684/4885SIGMAR1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.